Thursday, August 20, 2015
Sierra Leone awaits countdown to Ebola-free declaration
WHO: Protect medics in war zones
FDA approval of 'female Viagra' leaves bitter taste for critics
Addyi gains US marketing licence after third attempt, but questions remain about its effectiveness, potential side-effects and the true need for the drug
It is the small pink pill that its manufacturers hope will do for women what Viagra did for men. The decision to give the drug a marketing licence in the US has been cheered on by campaigners for women’s rights, but the question remains whether Addyi is the breakthrough medicine claimed.
Men have the blue diamond-shaped Viagra pill and 25 others (although 17 of those are forms of testosterone), while there has until now been no counterpart for women. But sex and relationship therapists say Addyi is only moderately effective, should not be taken with alcohol, and has potentially serious side-effects. Trials showed that Addyi gave women who took it daily one extra sexually satisfying experience per month.
Related: FDA approves 'female Viagra' pill Flibanserin after two rejections
Continue reading...Researchers identify brain region that deciphers between new and old memories
MRI scans can deliver cancer therapy
Innovative solutions to the NHS funding gap – cartoon
Keeping the health service free at the point of entry may result in some compromises
Continue reading...